Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07128212) titled 'Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).
Primary Sponsor: Suzhou Municipal Hospital of Anhui Province
Condition:
Ischemic White Matter Lesions (WMIL)
Cerebral Small Vessel Disease
Vascular Cell Adhesion Molecule-1
VCAM-1
Intervention:
Drug: Atorvastatin 10 mg daily
Recruitment Status: Not recruiting
Phase: N/A
Date of First Enrollment: January 1, 2021
Target Sample Size: 401
Coun...